AKT1 and plasma cell myeloma: In addition to Jak, PI3K, Akt, and mTOR inhibitors, we tested other drugs that have an effect on malignant lymphoma or multiple myeloma in vitro and in vivo including proteasome inhibitors, melphalan, pomalidomide, and histone deacetylase (HDAC) inhibitors.